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Abstract
Introduction: Hepatoid adenocarcinoma is a special type of extrahepatic alpha-fetoprotein-
producing adenocarcinoma, which has a morphologic similarity to hepatocellular carcinoma. We
report a patient with underlying hepatitis B virus infection and hepatoid adenocarcinoma with liver
metastasis mimicking hepatocellular carcinoma.
Case presentation: We present the case of a 56-year-old Chinese female with underlying hepatitis
B virus infection, who was found to have multiple hepatic tumors by abdominal ultrasound and an
elevated level of serum alpha-fetoprotein. Hepatocellular carcinoma was considered based on the
image findings, the elevated level of serum alpha-fetoprotein. and underlying hepatitis B virus
infection. Moreover, the subsequent endoscopy revealed gastric tumor. However, the tumor
histology of the stomach and liver revealed glandular adenocarcinoma with hepatoid foci. The final
diagnosis is hepatoid adenocarcinoma of the stomach with liver metastasis.
Conclusion: Hepatoid adenocarcinoma is an aggressive tumor with liver metastasis being the first
clinical manifestation of the neoplasm. Hepatoid adenocarcinoma of the stomach with liver metastasis
should be considered in older patients with elevated serum alpha-fetoprotein and multiple hepatic
tumors with underlying chronic liver disease. An upper gastrointestinal endoscopy should be
performed to exclude the possibility of hepatoid adenocarcinoma originating from the stomach to
avoid potential misdiagnosis and inappropriate therapy.
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Introduction
Hepatoid adenocarcinoma (HAC) is a special type of
extrahepatic adenocarcinoma, which has a morphologic
similarity to hepatocellular carcinoma (HCC) [1]. The first
case was described by Bourreille et al. in 1970 [2]. HCC
and HAC share numerous clinicopathological features
like an elevated level of serum alpha-fetoprotein (AFP),
hepatoid morphology and immunoreactivity with AFP
and polyclonal carcinoembryonic antigen (CEA) [3].
Thereby, HAC of the stomach with liver metastasis may
closely mimic and be indistinguishable form HCC [1].
This makes the differential diagnosis challenging, espe-
cially, when the primary tumor is unknown and the
first diagnosis has to be established by liver biopsy.
Herein, we report a rare case of HAC of the stomach with
liver metastasis and underlying hepatitis B virus (HBV)
infection which was difficult to differentiate from HCC,
particularly in a region with a high prevalence of HCC.
Case presentation
A 56-year-old Chinese female presented on admission to
our gastroenterology ward on May 2007, with a history
of abdominal dull pain of 2 weeks duration and a weight
loss of 6 kg duration a 2-month period. The abdominal pain
became progressively worse and most tender in the right
upper quarter (RUQ). She had had HBV infection for
15 years but follow up was irregular. She denied alcohol or
smoking history. Result of physical examination showed
RUQ tenderness and hepatomegaly. Results of laboratory
workup revealed aspartate aminotransferase level of
130 IU/L, alanine aminotransferase level of 50 IU/L, total
bilirubin level of 0.6 mg/dl and alkaline phosphatase
level of 609 IU/L. The level of serum AFP was elevated
(9457 ng/ml) but the levels of CEA and carbohydrate
antigen19-9 (CA19-9)werewithin the normal range. Serum
was positive for hepatitis B surface antigen (HBsAg), but
negative for HBeAg. The serum anti-HCV was also negative.
Abdominal ultrasound (US) demonstrated multiple hepa-
tic tumors at the bilateral lobe and mild chronic liver
disease. Abdominal computed tomography (CT) showed
multiple hepatic tumors sized 3-7 cm in the bilateral lobes
of the liver and wall thickening in the stomach (Figure 1A).
No cirrhotic change was observed. Based on the image
findings, the elevated AFP and underlying HBV infection
of the patient, HCC was highly suspected and a US-guided
liver biopsy was performed for definite diagnosis
(Figure 2A). Subsequent upper GI endoscopy also revealed
a 5-cm slight protruding tumor with a central ulceration at
the great curvature extending from the low body to antrum
of the stomach (Figure 1B).
Gastric biopsy revealed a moderately differentiated
tubular adenocarcinoma and poorly differentiated adeno-
carcinoma morphologically (Figure 2B). However, the
histopathological and immunohistochemical (IHC) find-
ings demonstrated that tumor in the stomach is character-
ized by an admixture of tubular adenocarcinoma with
hepatoid component and the tumor in liver showed
hepatoid differentiation with identifiable glandular struc-
ture (Figure 2A and 2B). The results of IHC study revealed
reactivity to Hepatocyte paraffin 1 (Hep Par 1), AFP, and
polyclonal and monoclonal CEA in the tumors of both
liver and stomach (Figure 2C and 2D). The final diagnosis
in this case was HAC of the stomach with liver metastasis.
She underwent chemotherapy with Mitomycin-C,
5-fluorouracil and Doxorubicin. The tumor of the stomach
was in six courses of complete remission (Figure 1C) and
the serum AFP returned to within the normal range after
six course chemotherapy. Furthermore, the metastatic liver
tumors were partly remission. Careful follow-up of this
patient revealed recurrence of the liver metastases with
tumor rupture (Figure 1D). The patient died 20 months
after disease diagnosis.
Discussion
AFP is detected in the serum of adults with HCC,
hepatoblastoma, those with germ cell tumor (especially
yolk sac tumor), and those with non-cancerous liver disease
with liver regeneration, such as hepatitis and cirrhosis.
AFP-producing malignant tumors have been reported in
several different organs such as the lung, pancreas, colon,
ovary and urinary bladder [4-8]. The stomach is one of the
most common sites affected by these tumors, and the first
such case was reported by Bourreille et al. in 1970 [1].
Ishikura et al. proposed the term ‘hepatoid adenocarcinoma
of the stomach’ for primary gastric carcinomas characterized
by both hepatoid differentiation and the production of
large amounts of AFP [9]. The reported incidences of
AFP-producing gastric adenocarcinoma have been from
1.3%-15% of all gastric cancers [4,5]. Clinically, the
neoplasm is characterized by older age, an aggressive clini-
cal course, and poor survival [1,4-8]. Its biologic behavior is
due to its extensive hematogenous metastasis to the liver
and to its early involvement of lymph nodes [1,5].
The diagnosis of HAC depends on recognition of the
characteristic histological features [5]. The histological find-
ing reveals glandular adenocarcinoma with hepatoid foci
[6]. The IHC staining affordsmore special support but it dose
not constitute a definite diagnosis for HAC. The IHC staining
has not also been helpful in distinguishing between meta-
staticHACandHCC[3].Demonstrationof theproductionof
albumin mRNA provides specific support for a diagnosis of
hepatocyte differentiation [10]. It is important to ensure the
accurate diagnosis of an AFP-producing HAC of stomach as
a result of the extremely poor prognosis.
The resemblance of HAC to HCC may be problematic in
the diagnosis of hepatic tumors. In our study, multiple
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hepatic tumors were the first tumor manifestation and the
patient had underlying HBV infection and markedly
elevated AFP. Thus, the diagnosis of HCA presenting
as hepatic tumors may be a great challenge for the
pathologist and clinician, and the differential diagnosis
of HAC fromHCC is difficult. HCCs arising in non-fibrotic
liver and without underlying known risk factors are rare,
but according to a European study they may represent up
to 13% of HCCs [11]. However, this group often appears
as a single tumor [12]. Although multiple hepatic tumors
without cirrhotic change were found in our study, HCC
had been diagnosed in our case because she had multiple
hepatic tumors, underlying HBV infection and markedly
elevated AFP. Even if the first diagnosis is established by
liver biopsy, misdiagnosis as HCC can still occur because
the hepatic tumor bears a striking morphologic similarity
to HCC in histology and IHC staining especially when a
case happens in a region of high prevalence of HCC such
as in Taiwan. Therefore, if the extrahepatic origin is not
detected by endoscopy, the misdiagnosis and inappro-
priate therapy may follow.
In our study, the tumor of both stomach and liver was
positive for Hep Par1. Hep Par 1 is a developedmonoclonal
antibody that reacts with a hepatocyte-specific epitope [13].
An 82% sensitivity and 90% specificity for Hep Par1
have been reported in HCC, suggesting that this antibody
might be the most sensitive and specific IHC marker for
hepatocyte differentiation [1]. Furthermore, some studies
have reported a focal positivity for Hep Par1 in 13% to 85%
of carcinoma with hepatoid differentiation [1,14,15]. The
presence of Hep Par 1 reactivity in extrahepatic HACs
Figure 1. (A) Endoscopy reveals a protruding tumor with a central ulceration at the great curvature extending from the low
body to antrum of the stomach. (B) Abdominal CT shows multiple hepatic tumors in the bilateral lobes of the liver and wall
thickening in the stomach. (C) Endoscopy reveals complete remission of the gastric tumor after chemotherapy. (D) Abdominal
CT shows the recurrence of the liver metastases with tumor rupture.
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underscores the fact that Hep Par 1 expression is not unique
to primary HCCs. Adenocarcinoma with hepatoid features
must be considered in the differential diagnosis of Hep Par
1-positive lesions.
Conclusion
HAC is an aggressive tumor with liver metastasis being the
first clinical manifestation of the neoplasm. HAC of the
stomach with liver metastasis should be considered in
older patients with elevated serum AFP and multiple
hepatic tumors with underlying chronic liver disease. An
upper GI endoscopy should be performed to exclude the
possibility of HAC originating from the stomach.
Although rare, this entity deserves wide recognition
among pathologists and clinicians to avoid potential
misdiagnosis and inappropriate therapy.
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Figure 2. (A) Tumor in liver shows glandular structure with eccentrically located nuclei and with hepatoid differentiation.
(B) Tumor in stomach shows an admixture of tubular adenocarcinoma with hepatoid component. (C), (D) Tumors in liver and
stomach reactive to hepatocyte paraffin 1 immunohistochemically, suggestive of hepatoid differentiation.
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